The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. 4D Molecular Therapeutics Inc shares valued at $259,102 were sold by Bizily Scott on Apr 01 ’24. At $31.78 per share, Bizily Scott sold 8,153 shares. The insider’s holdings dropped to 1,737 shares worth approximately $48114.9 following the completion of this transaction.
Also, Bizily Scott sold 5,833 shares, netting a total of over 204,410 in proceeds. Following the sale of shares at $35.04 each, the insider now holds 1,737 shares.
Before that, Bizily Scott had sold 1,750 shares from its account. In a trade valued at $54,722, the Chief Legal Officer traded 4D Molecular Therapeutics Inc shares for $31.27 each. Upon closing the transaction, the insider’s holdings decreased to 1,750 shares, worth approximately $48114.9.
Analysts at RBC Capital Mkts started covering the stock with ‘”an Outperform”‘ outlook in a report released in late October. As of October 24, 2023, Cantor Fitzgerald has initiated its “an Overweight” rating for FDMT. Earlier on October 18, 2023, Leerink Partners upgraded its rating. Their new recommendation was “an Outperform” for FDMT stock which previously was a “a Market perform”.
Analyzing FDMT Stock Performance
During the last five days, there has been a surge of approximately 0.22%. Over the course of the year, 4D Molecular Therapeutics Inc shares have jumped approximately 36.72%. Shares of the company reached a 52-week high of $36.25 on 03/27/24 and a 52-week low of $16.64 on 01/19/24. A 50-day SMA is recorded $28.68, while a 200-day SMA reached $18.82. Nevertheless, trading volume fell to 0.65 million shares from 0.55 million shares the previous day.
Support And Resistance Levels for 4D Molecular Therapeutics Inc (FDMT)
According to the 24-hour chart, there is a support level at 26.91, which, if violated, would cause prices to drop to 26.12. In the upper region, resistance lies at 28.18. The next price resistance is at 28.65. RSI (Relative Strength Index) is 44.12 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.87, which suggests the price will decrease in the coming days. Percent R is at 80.89%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is 4D Molecular Therapeutics Inc subject to short interest?
Stocks of 4D Molecular Therapeutics Inc saw a sharp rise in short interest on Mar 15, 2024 jumping by 1.44 million shares to 8.5 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 7.06 million shares. A jump of 16.94% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.54 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.54.
